SBC vs NVCR vs INMD vs HOLX

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -6. 2% for InMode Ltd. (INMD). SBC Medical Group Holdings Incorporated (SBC) offers the better valuation at 6. 7x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate SBC Medical Group Holdings Incorporated (SBC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, SBC Medical Group Holdings Incorporated (SBC) is the cheapest at 6.

7x versus Hologic, Inc. at 30. 5x. On forward P/E, SBC Medical Group Holdings Incorporated is actually cheaper at 7. 1x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus SBC's -67. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -6. 2% for InMode Ltd. (INMD). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBC leads at 34. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, SBC Medical Group Holdings Incorporated (SBC) trades at 7.

1x forward P/E versus 17. 2x for Hologic, Inc. — 10. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SBC: 180. 4% to $9. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SBC (Industrials) and NVCR (Healthcare) and INMD (Healthcare) and HOLX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SBC is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; INMD is a small-cap deep-value stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.